by Kirsten Chalmers | Aug 17, 2022 | Health technology assessment, Healthcare, Market access, NICE
Designed to help healthcare stakeholders identify more urgent health needs, the concept of “unmet medical need” is being increasingly applied formally and informally to set priorities during the development, assessment, and reimbursement of new drugs and medical...
by Anna Pagotto | Jul 6, 2021 | Market access, NICE, Oncology
The rapid development of immuno-oncology (I-O) therapies has transformed the cancer treatment landscape, but health technology assessment (HTA) agencies can decide against covering or reimbursing such treatments because of their complexity and high cost. As experts in...
